Artificial Intelligence in the Pharma Industry
The pharmaceutical industry has taken an increased interest in advanced analytics in the last decade with about 50% believing that technologies like artificial intelligence (AI) will relieve pressure on their companies and allow them to bring new drugs to market more quickly. From drug discovery and development to product formulation, manufacturing and post-market surveillance, we are seeing incredible advancements with the application of artificial intelligence in the pharma industry.
Digitalization, inclusive of artificial intelligence and machine learning, is a key component of Industry 4.0, the ISPE’s Pharma 4.0 Initiative and the FDA’s Advanced Manufacturing Initiatives. Those that are using pharma data analytics and who are pioneering the adoption of artificial intelligence in the pharma industry will be the companies that steer progress and innovation in our digital era.
What does digitalization and artificial intelligence in the pharma industry look like on a grand scale, though?
One of the best use cases for artificial intelligence in the pharma industry is in drug discovery. Overall, the use of AI can accelerate drug research and development, yielding a commercialized medicine that makes it way to consumers much more quickly. By harnessing the power of AI to design medicines with manufacturing in mind, companies can also proactively address challenges of tech transfer and scale-up, which are the biggest bottlenecks when moving a drug from development to production. With the use of artificial intelligence in the pharma industry, companies can identify learnings and continuously improve their processes to enable more realistic storage and shipping conditions, optimize distribution channels and ultimately provide broader access to medicines.
The use of predictive analytics in the pharmaceutical industry is also proving instrumental in improving efficiencies across the product lifecycle. According to McKinsey, pharmaceutical companies show an estimated 70% improvement in overall equipment effectiveness with the use of artificial intelligence. Naturally, this can have a trickle-down effect on pharma’s ability to make medicine more available and less expensive, without sacrificing margins.
In addition, efficiencies can be gained across the supply chain in the pharmaceutical industry by using AI to optimize planning and scheduling across a multitude of variables that would be impossible for humans, allowing for much greater agility and resiliency across the pharma value chain network. This agility enables real-time accommodations to shifts in supply and demand, improved decision making and the shift of workers’ responsibilities to more value-added tasks instead of being mired in the constant cycle of manually adjusting and readjusting planning and scheduling models.
Releasing a single lot of pharmaceutical product has traditionally been a very manual and labor-intensive process – from ensuring quality materials are sourced to processes being executed properly according to SOPs and subsequently released with all the required documentation, audit trails and signatures. A single lot release could easily generate a ream of paper. With automation and digital in pharma, the possibility of bridging Operations with Quality Control can become a reality. Documentation is accessed through a central repository, making sign-off significantly easier and faster. This means that product is not sitting in inventory and can be shipped sooner. Going digital with analytics in pharma means greater efficiencies across the board so the company can see shorter review cycles, improved rates of production and profitability.
Real World Data and Real-World Evidence
There is a wealth of post-market surveillance data for any drug that reaches the marketplace, and these data are mined to understand negative outcomes as well as expanded intended use scenarios. Because of the volume of data being generated from a variety of sources, AI has been a huge enabler for analyzing the data to inform better decision making. In addition, these real-world data can help companies identify more targeted cohorts for future clinical trials, which can equate to millions of dollars saved and faster time to market for future development projects.
Machine learning in pharma will provide even more benefit with the continued growth of complex modalities, personalized medicine and smaller batch sizes. With the enablement of cloud deployments, aggregation of the data will become less of an issue, and the companies that are clear on what questions they are trying to answer and what problems they are trying to solve will be the companies that leapfrog others on their paths to digital maturity.
What is Blockchain in pharma?
Pharmaceuticals are one of the most tightly regulated industries in the world, as patients' safety is of utmost importance. However, this tight regulation also creates several challenges for pharmaceutical manufacturers.
One such challenge is the track and traceability of drugs throughout the manufacturing process. Each stage of drug development and production must be meticulously documented and tracked, from ingredient sourcing to end product release.
This is a complex process that requires a great deal of coordination and communication between different stakeholders within the supply chain. Blockchain technology has the potential to help solve many of these tracking and tracing challenges.
How has technology changed the pharmaceutical industry?
Technology has dramatically changed the pharmaceutical industry in several ways.
For one, it's made the process of drug development much more efficient. Researchers can now use computers to design new drugs, and 3D printers can be used to create precise replicas of human organs, which can then be used for drug testing.
Artificial intelligence (AI) is being used to develop personalized treatments for patients based on their individual genetic profiles.
And cloud-based technologies are a means to aggregate data that may once have been segregated and siloed. Increasing data accessibility and data sharing will continue to open new opportunities for partnerships as we strive to improve global access to medicine.
Executive Brief:
Optimizing Outcomes Across the Pharma Value Chain Network
Report:
Culture Reimagined: How Pharmaceutical Firms Can Use Data and AI with Confidence
Case Study:
GSK Creates a Future-Ready Supply Chain with Predictive and Prescriptive Maintenance
White Paper:
Digitalization for Pharmaceuticals: Safeguarding Product Supply by Ensuring Asset and Process Health